Company intelligence / Profile preview

AcornMed

Ownership: Private
Development stage: Commercial

Overview

AcornMed has developed over 30 clinical testing products covering early detection/screening of multiple cancers, hereditary risk identification, companion diagnostics for targeted therapy/immunotherapy selection and monitoring. Their non-invasive urine-based tests have received medical device licenses in China. They serve more than 500 hospitals nationwide

Therapeutic areas: Oncology
Modalities: Diagnostic test (genomic/NGS-based)
Industry: Molecular Diagnostics

Drug pipeline

3 assets

UI-SEEK

Commercial

Indications: Urothelial carcinoma

2 more assets in the full pipeline.

Request access →

Partnerships

Twist Bioscience – partnership to use Twist’s NGS panels for precision medicine testsNuProbe – strategic collaboration to develop minimal residual disease detection products using BDA technology

Beyond the preview

Go deeper on AcornMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AcornMed.

Explore the full profile